奥泰生物: 国元证券股份有限公司关于杭州奥泰生物技术股份有限公司2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件事项之独立财务顾问报告

Core Viewpoint - The report outlines the independent financial advisory opinion regarding the third vesting period and the reserved grant of the second vesting period under the 2022 Restricted Stock Incentive Plan of Hangzhou Aotai Biotechnology Co., Ltd, confirming that the conditions for vesting have been met [1][12][19] Group 1: Incentive Plan Overview - The 2022 Restricted Stock Incentive Plan includes provisions for granting restricted stocks to eligible participants, including directors, senior management, and key technical personnel [1][4] - The first grant date for the restricted stocks was July 22, 2022, with the third vesting period commencing 36 months after this date [12][13] - The total number of restricted stocks eligible for vesting is 438,890 shares, with 409,472 shares from the first grant's third vesting period and 29,418 shares from the reserved grant's second vesting period [12][19] Group 2: Approval Process - The approval process for the incentive plan involved multiple meetings, including the second board meeting on June 27, 2022, where the plan was reviewed and approved [5][6] - The plan was publicly disclosed on the Shanghai Stock Exchange website on June 28, 2022, following the board's approval [6][7] - Subsequent meetings were held to verify the eligibility of the incentive recipients and to approve the reserved grants, with the latest meeting occurring on April 28, 2023 [8][9] Group 3: Vesting Conditions - The vesting conditions for the restricted stocks include the absence of adverse audit opinions and the fulfillment of performance targets related to business revenue and research and development [13][14] - The performance targets set for the first vesting period include achieving a business revenue of at least 6.01 billion yuan and obtaining regulatory approvals for a minimum of 15 self-developed medical device products [17][18] - The report confirms that the conditions for vesting have been satisfied, allowing the eligible participants to receive their shares [12][19]